louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02919202: Clinical Trial to Compare the Efficacy of a Fluoride Gel and a Dental Bonding Agent in Treatment of Tooth Sensitivity
Official title: A Randomised Controlled Trial Investigating a Comparison of Fluoride Varnish vs Self-Etching Dentine Bonding Agent in the Reduction of Cervical Dentine Sensitivity in Patients Attending a General Dental Practice in West Sussex, UK.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dentin Sensitivity
Lead sponsor: University of Kent
Sponsor class: OTHER
First posted: 2016-09-29
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study compares the efficacy of two dental interventions in the treatment of cervical dentine sensitivity. The participants will be selected from adult dental patients registered at a general dental practice in West Sussex, UK. The participants will be split into 2 groups. One group will receive the intervention of topical fluoride varnish application while the other group will receive a topical application of self-etching dentine bonding agent.

Detailed description: Topical Fluoride Varnish(TFV) and Self-Etching Dentine Bonding Agent (SEDBA) are both routinely used in dentistry in the management of cervical dentine sensitivity(CDS). Both interventions are topically applied and well tolerated by patients. The interventions differ in mechanism of action. TFV releases fluoride which is incorporated into the organic matrix of dentine making the dentine tubules less conductive. Dentinal tubules form the key conduit between stimulus and pain perception in the tooth. SEDBA differs in that it penetrates and occludes the tubules. It is light cured for an almost instant set time.

Eligibility criteria: Inclusion Criteria:

* Aged 18-60.
* Exhibiting CDS elicited by the two test stimuli in relation at least one tooth.

Exclusion Criteria:

* Patients who have undergone comprehensive periodontal treatment in the past 3 months.
* Patients under the age of 18 or unable to provide valid consent.
* Teeth that have visible fracture lines, caries, crowns or have been endodontically treated.
* Patients taking analgesic medication for any systemic conditions.

Primary outcomes:
measure: Visual Analogue Scale
timeFrame: 14 days
Secondary outcomes:
Other outcomes:
Locations:
city: Horsham
country: United Kingdom
facility: Carfax Dental Practice
state: West Sussex
Study officials:
affiliation: University of Kent
name: Claire Parkin, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03551002: Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego
Official title: Impact of Direct Acting Antivirals Uptake in Controlling Hepatitis C Epidemic and Modeling Interventions for Hepatitis C Elimination Among HIV-infected Persons in San Diego
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hepatitis C
Hepatitis C, Chronic
HIV/AIDS
Keywords: HIV
Hepatitis C
Direct acting antivirals
Hepatitis C modeling
Lead sponsor: University of California, San Diego
Sponsor class: OTHER
First posted: 2018-06-11
Enrollment: 450
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: People living with HIV, with history of or current HCV infection, who receive care at the UCSD Owen Clinic from 2008 to 2020

Brief summary: A retrospective and prospective study among people living with HIV (PLWH) that assesses hepatitis C (HCV) treatment uptake during periods before and after direct acting antivirals (DAA) introduction, and its impact on the HCV epidemic among PLWH.

Detailed description: A study that aims to quantify the state of DAA uptake and its impact on the HCV epidemic among PLWH in San Diego, and to characterize negative predictors of DAA treatment uptake among PLWH in San Diego. Retrospective and prospective data from UCSD Owen Clinic will be utilized to calculate HCV prevalence, primary incidence, and reinfection incidence. Using mathematical epidemic models, the study will assess levels of existing and scaled-up interventions necessary for HCV elimination from PLWH in San Diego.

Eligibility criteria: Inclusion Criteria:

* Any adult (≥ 18 years) HIV-infected patient attending the UCSD Owen Clinic
* With history of acute or chronic HCV infection defined as having a detectable HCV viral load with or without a positive HCV antibody

Exclusion Criteria:

* With no history of or current HCV infection defined as having a negative HCV antibody from 2008 to 2020

Primary outcomes:
measure: Annual proportion of HIV-infected patients who initiate direct acting antivirals
timeFrame: 2014-2020
Secondary outcomes:
measure: Annual proportion of PLWH co-infected with HCV who are treatment naïve, previously treated with no sustained virologic response (SVR), or re-infected post-SVR
timeFrame: 2008-2020
measure: Annual HCV chronic prevalence, primary incidence, and reinfection incidence among HIV-infected patients
timeFrame: 2008-2020
Other outcomes:
measure: Estimated HCV prevalence and incidence among PLWH in San Diego using dynamic transmission modeling calibrated to epidemiological data from outcomes described above
timeFrame: 2008-2030
Locations:
city: San Diego
country: United States
facility: Owen Clinic-University of California, San Diego
state: California
Study officials:
affiliation: University of California, San Diego
name: Edward Cachay, MD, MAS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01331902: Comparison of Hyperemic Efficacy Between Nicorandil and Adenosine for Fractional Flow Reserve (FFR) Measurement
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Coronary Artery Disease
Myocardial Ischemia
Keywords: Adenosine
Nicorandil
Fractional Flow Reserve
Maximal Hyperemia
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
Collaborators: name: Seoul National University Boramae Hospital
name: Inje University Ilsan Paik Hospital
name: Keimyung University Dongsan Medical Center
First posted: 2011-04-08
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to evaluate the efficacy of nicorandil in the achievement of maximal coronary hyperemia compared with adenosine.


Eligibility criteria: Inclusion Criteria:

* non -infarct related, patients with moderate coronary artery stenosis
* normal left ventricular ejection fraction on echocardiogram

Exclusion Criteria:

* infarct-related arteries or clinically unstable state
* collateral blood flow to the target vessel is shown
* atrioventricular block on electrocardiogram
* reduced left ventricular ejection fraction (\<50%) or left ventricular hypertrophy on echocardiogram
* contraindication of adenosine
* bronchial asthma

Primary outcomes:
measure: Fractional Flow Reserve at Maximal Hyperemia
timeFrame: 1 day
Secondary outcomes:
measure: Time to Maximal Hyperemia
timeFrame: 1 day
measure: Changes in Heart Rate
timeFrame: 1 day
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Cardiovascular Center, Seoul National University Hospital
Study officials:
affiliation: Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital
name: Bon-Kwon Koo, MD. PhD
role: STUDY_CHAIR
References:
citation: Jang HJ, Koo BK, Lee HS, Park JB, Kim JH, Seo MK, Yang HM, Park KW, Nam CW, Doh JH, Kim HS. Safety and efficacy of a novel hyperaemic agent, intracoronary nicorandil, for invasive physiological assessments in the cardiac catheterization laboratory. Eur Heart J. 2013 Jul;34(27):2055-62. doi: 10.1093/eurheartj/eht040. Epub 2013 Feb 8.
Clinical trial NCT00033202: This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor
Official title: Phase I Study of Oral ST1481 Administered Once Weekly Every 3 Out 4 Weeks in Patients With Advanced Solid Malignancies.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Solid Malignancies
Keywords: Solid Tumor
Camptothecin
Pharmacokinetics
Lead sponsor: Sigma-Tau Research, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Rhode Island Hospital
name: Dana-Farber Cancer Institute
First posted: 2002-04-10
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Gimatecan® is sigma-tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this class play a crucial role in destroying DNA replication in tumors. We are conducting this study to determine the Maximum Tolerated Dose of our compound, when given as a capsule, rather than by intravenous injection.


Eligibility criteria: Inclusion criteria:

* Histologically/cytologically proven advanced solid tumors
* Life expectancy of at least 3 months with normal hematological, liver and renal function

Exclusion criteria:

* Pregnant and lactating patients
* Participation in any investigating drug study within 4 weeks preceding treatment start or concurrent treatment with any other anti-cancer therapy
* Gastrointestinal dysfunction that could alter absorption or motility

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
city: Providence
country: United States
facility: Rhode Island Hospital
state: Rhode Island
Study officials:
References:
Clinical trial NCT05818202: Perspections of Stroke Patients and Physiotherapists in Robotic Rehabilitation
Official title: Experiences, Attitudes, and Perspectives of Stroke Patients and Physiotherapists in Robotic Rehabilitation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Stroke; Paralysis
Physician's Role
Lead sponsor: Pamukkale University
Sponsor class: OTHER
First posted: 2023-04-18
Enrollment: 107
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Fifty stroke patients and fifty seven physiotherapists were participated in the study. All participants met the inclusion criteria.

Brief summary: This study was a cross-sectional study. The insights of stroke patients and physiotherapists were assessed with the quantitative questionnaires. The results were provided as number, percentage, mean, and standard deviation. The results of the insights of the current sapmle were given and compared the previous studies. The authors though that the results of the study can fill the gaps in robotic rehabilitation and support a better robotic rehabilitation experience.

Detailed description: Fifty stroke patients and fifty seven physiotherapists included the study. A seventeen-item and eight-item questionnaire s were created for stroke patients and physiotherapists, respectively. The descriptive data of the stroke patients and physiotherapists were presented. The results were compared with the literature and interpreted to guide future studies.

Eligibility criteria: For stroke patients

Inclusion Criteria:

* Having a single stroke

Exclusion Criteria:

* Having a communication problem
* Having another neurological condition which can affect the study

For physiotherapists

Inclusion Criteria:

* Graduating from a physiotherapy and rehabilitation program with at least a bachelor degree
* Working in Denizli

Exclusion Criteria:

-

Primary outcomes:
measure: A seventeen-item questionnaire
timeFrame: 1 year
measure: An eight-item questionnaire
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Denizli
country: Turkey
facility: Pamukkale University
state: Pamukkale
Study officials:
affiliation: Pamukkale University
name: Güzin Kara Çakıcı
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00002102: A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia.
Official title: A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pneumonia, Pneumocystis Carinii
HIV Infections
Keywords: Trimetrexate
Pneumonia, Pneumocystis carinii
Leucovorin
Drug Therapy, Combination
Acquired Immunodeficiency Syndrome
Lead sponsor: NIH AIDS Clinical Trials Information Service
Sponsor class: INDUSTRY
First posted: 2001-08-31
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: To provide trimetrexate glucuronate to immunosuppressed patients with Pneumocystis carinii pneumonia (PCP) for whom this investigational compound could provide significant medical benefit.

Detailed description: Patients receive intravenous infusions of trimetrexate glucuronate and leucovorin for 21 days. Leucovorin is continued for 3 additional days after discontinuation of trimetrexate glucuronate.

Eligibility criteria: Inclusion Criteria

Concurrent Medication:

Allowed:

* Antiretroviral therapy (at the discretion of the treating physician and/or medical monitor).

Patients must have:

* Presumptive or definitive diagnosis of Pneumocystis carinii pneumonia (PCP).
* HIV positivity or be otherwise immunosuppressed.
* Demonstrated intolerance and/or resistance to trimethoprim/sulfamethoxazole during the course of therapy for the current episode and not candidates for parenteral pentamidine, OR a documented history of such intolerance during a prior episode.
* Consent of parent or guardian if less than 18 years of age.

NOTE:

* In general, patients who meet the eligibility criteria for other U.S. Bioscience-sponsored clinical trials for trimetrexate would not be eligible for this Compassionate Use protocol.

Exclusion Criteria

Patients with the following prior conditions are excluded:

History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis), exfoliative dermatitis, or other life-threatening reactions to trimetrexate.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: West Conshohocken
country: United States
facility: United States Bioscience Inc
state: Pennsylvania
Study officials:
References:
citation: Feinberg J, McDermott C, Nutter J. Trimetrexate (TMTX) salvage therapy for PCP in AIDS patients with limited therapeutic options. Int Conf AIDS. 1992 Jul 19-24;8(2):B136 (abstract no PoB 3297)
Clinical trial NCT07015502: Self-Dehumanization and Hesitation to Report Domestic Violence
Official title: Self-Dehumanization and Hesitation to Report Domestic Violence
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Domestic Violence
Lead sponsor: Centre Hospitalier Henri Laborit
Sponsor class: OTHER
First posted: 2025-06-11
Enrollment: 84
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: women victims of domestic violence

Brief summary: The patients included in the study will be adult women who are victims of domestic violence, consulting for this reason. The duration of participation of each patient will be one hour.

After obtaining the patient's non-opposition to her participation in the study, socio-demographic and history of violence suffered will be collected during an interview with the doctor/nurse. After that, the hetero-questionnaire MADRS (Montgomery-Asberg Depression Rating Scale) will be administered to the patient. This first part will last 30 minutes.

The second part of the study, carried out immediately after the interview, will be carried out on computer in the form of 4 self-questionnaires (Childhood Trauma Questionnaire, Deshumanization Measure within Romantic Relationships scale, self-esteem scale, violentometer) and an implicit association test (IAT). This second part will last 30 minutes.

Then, the participation of the patient in the study is over.


Eligibility criteria: Inclusion Criteria:

* Woman over 18
* Victim of physical and/or psychological domestic violence taken into care for this reason, following an initial complaint
* Understanding and speaking French
* Subject affiliated to a social security scheme

Exclusion Criteria:

* Patient under legal protection measure (guardianship or legal protection)
* Presence of a disabling mental or cognitive disorder
* Patient employed by the investigator

Primary outcomes:
measure: Assessment of the correlation between the process of personal dehumanization in victims of domestic violence and their hesitation to file a complaint against the aggressor partner.
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Poitiers
country: France
facility: CH Henri Laborit
state: Vienne (86)
city: Poitiers
country: France
facility: CHU Poitiers
state: Vienne (86)
Study officials:
References:
Clinical trial NCT02388802: Human Clinical Trial of Uterine Transplantation in the United Kingdom
Official title: The First Human Clinical Trial of Uterine Transplantation in the United Kingdom
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Infertility
Keywords: Infertility
Transplant
IVF
Hysterectomy
Absolute uterine infertility
Lead sponsor: Womb Transplant UK
Sponsor class: OTHER
Collaborators: name: Imperial College London
First posted: 2015-03-17
Enrollment: 10
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 36
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Ten patients will undergo uterine transplantation.

Detailed description: Ten patients that will be appropriately selected using a variety of physical and psychological assessments. The selected patients will undergo egg retrieval and subsequent freezing of embryos to enable IVF treatment following transplantation. Following uterine transplantation, using deceased donor allografts, the patients will be closely monitored for 12 months clinically, radiologically and immunologically until embryo transfer. Following successful embryo transfer the patients will continue to be monitored antenatally until they are delivered by Caesarean section.

Eligibility criteria: Inclusion Criteria:

* Female
* Between 18-36 years of age
* Absolute Uterine factor infertility

Exclusion Criteria:

* Poor ovarian reserve - Unsuccessful oocyte retrieval
* No intercurrent significant medical or psychiatric co-morbidities
* Previous oncology patients \<5 years in remission
* Outside of age range
* Normal BMI

Primary outcomes:
measure: Transplant success
timeFrame: 12 months
Secondary outcomes:
measure: Pregnancy rate
timeFrame: 24 months
measure: Live birth rate
timeFrame: 36 months
Other outcomes:
Locations:
Study officials:
affiliation: Imperial NHS Healthcare Trust
name: Richard Smith, FRCOG, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00238602: Evaluation of Cyberknife Precision Radiation Delivery System for Unresectable Malignant Lung Cancer
Official title: Evaluation of the Cyberknife Precision Radiation Delivery System for Unresectable Malignant Lung Tumors - A Phase I/II Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Lung Cancer
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2005-10-13
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study has two primary objectives. The first objective is to determine the maximal tolerated dose (MTD) that can be delivered with stereotactic radiosurgery in patients with inoperable malignant lung tumors. Once the MTD is established, the second objective is to determine the efficacy of radiosurgical ablation of lung tumors in terms of symptoms and radiographic responses.


Eligibility criteria: Inclusion Criteria:1.Lung tumor \>= 5.0 cm.

2.Age \> 18 years,

3.Histologic confirmation of malignancy (primary lung or metastatic tumor)

4.Deemed unresectable either by radiographic criteria (such as direct invasion of the mediastinum, heart, great vessels, or trachea), by virtue of excessive risk to patient, patient refusal to undergo surgery, or prior operative findings.

5.Performance status of 0-2 by Eastern Clinical Oncology Group criteria Exclusion Criteria:1. No chemotherapy within 2 weeks of radiation treatment.

2. Refusal to sign informed consent.

3. Refusal to take a pregnancy test prior to treatment if the patient is a woman with child bearing potential.

Primary outcomes:
measure: Maximal tolerated dose (MTD) that can be delivered with stereotactic radiosurgery in patients with inoperable malignant lung tumors
measure: Efficacy of radiosurgical ablation of lung tumors in terms of symptoms and radiographic responses
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Dr. Billy W. Loo Jr. M.D. Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: